Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Dose Ranging Study in Elective Total Hip Replacement Surgery (DRIVE)
This study has been completed.
Sponsored by: Sanofi-Aventis
Information provided by: Sanofi-Aventis
ClinicalTrials.gov Identifier: NCT00338897
  Purpose

The primary objective is to:

  • demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.

The secondary objectives are to:

  • evaluate the safety of SR123781A in the prevention of VTE after elective total hip replacement surgery; and
  • to assess the SR123781A pharmacokinetic profile in patients undergoing elective total hip replacement surgery.

Condition Intervention Phase
Venous Thromboembolism
 Drug: SR123781A
 Phase II
Phase III

Drug Information available for: Enoxaparin Sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Dose Comparison, Parallel Assignment, Efficacy Study
Official Title: A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:
  • The primary efficacy endpoint is a composite of total venous thromboembolic events (VTE) including VTE related deaths during the treatment period.

Secondary Outcome Measures:
  • Secondary efficacy endpoints will include all deep vein thrombosis events [DVTs] (proximal or distal) and all symptomatic VTEs (pulmonary embolisms [PEs] or DVTs)
  • The main safety criterion is the incidence of major bleedings occurring from the first study drug administration to 3 calendar days after the last study drug administration.

Enrollment: 1090
Study Start Date: May 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients scheduled to undergo elective total hip replacement surgery or a revision of at least one component of a total hip replacement performed > 6 months prior to study entry

Exclusion Criteria:

  • Pregnant or nursing women, or women of childbearing potential who are not using an effective contraceptive method and who do not have a negative pregnancy test performed immediately before randomization
  • Known progressive malignant disease
  • Ischemic stroke in the last 3 months
  • Myocardial infarction (MI) in the last 3 months
  • Any major orthopedic surgery in the 3 months prior to study start
  • Clinical signs or symptoms of DVT or PE within the last 12 months or symptoms of post phlebitic syndrome (these conditions may confound DVT/PE assessments)
  • Treatment with other antithrombotic agents within 7 days prior to surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00338897

Locations
Argentina, Buenos Aires
Sanofi-Aventis
San Isidro, Buenos Aires, Argentina, 1642
Bulgaria
Sanofi-Aventis
Sofia, Bulgaria, 1715
Chile, Santiago
Sanofi-Aventis
Providencia, Santiago, Chile
Colombia
Sanofi-Aventis
Santafe de Bogota, Colombia
Czech Republic
Sanofi-Aventis
Praha, Czech Republic, 160 00
Denmark
Sanofi-Aventis
Denmark, Denmark
Finland
Sanofi-Aventis
Helsinki, Finland
Mexico
Sanofi-Aventis
Mexico, Mexico, 04000
Norway
Sanofi-Aventis
Oslo, Norway
Poland
Sanofi-Aventis
Warszawa, Poland
Romania
Sanofi-Aventis
Bucuresti, Romania, 70334
Russian Federation
Sanofi-Aventis
Moscow, Russian Federation, 101000
Sweden
Sanofi-Aventis
Bromma, Sweden
Turkey
Sanofi-Aventis
Istanbul, Turkey, 34394
Sponsors and Collaborators
Sanofi-Aventis
Investigators
Study Chair: Michael Rud Lassen, MD Hoersholm Hospital, Spine Clinic, Usserod Kongevej 102, DK-2970 Hoerholm, Denmark
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Publications indexed to this study:
Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG. SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1498-504.

Responsible Party: sanofi-aventis ( ICD Study Director )
Study ID Numbers: DRI5664, EudraCT : 2006-000152-41
Study First Received: June 19, 2006
Last Updated: December 9, 2008
ClinicalTrials.gov Identifier: NCT00338897  
Health Authority: Russia: Pharmacological Committee, Ministry of Health;   Romania: National Medicines Agency;   Turkey: Ethics Committee

Keywords provided by Sanofi-Aventis:
Venous Thromboembolism
Prevention
Arthroplasty
 Replacement
Hip
orthopedic surgery

Study placed in the following topic categories:
Embolism and Thrombosis
Embolism
Vascular Diseases
Venous Thromboembolism
 Thrombosis
Thromboembolism
Enoxaparin

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services